← Product Code [OBO](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO) · K080460 # SPECTRAL OCT/SLO (K080460) _Opko Health, Inc. · OBO · Nov 14, 2008 · Ophthalmic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K080460 ## Device Facts - **Applicant:** Opko Health, Inc. - **Product Code:** [OBO](/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO.md) - **Decision Date:** Nov 14, 2008 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 886.1570 - **Device Class:** Class 2 - **Review Panel:** Ophthalmic ## Indications for Use The Spectral OCT/SLO is a non-contact, high-resolution non-invasive tomographic and confocal imaging device. It is indicated for in vivo viewing, axial cross-sectional, and three-dimensional imaging and measurement of posterior ocular structures including: retina, macula, retinanserve fibre layer and optic disk. It is used as a diagnostic device to aid in the detection and management of ocular diseases affecting the posterior segment of the eye. In addition, corners and conjunctiva can be imaged with the system by changing the focal position. ## Device Story Spectral OCT/SLO is a computerized, non-contact ophthalmic imaging system. It uses low-coherence interferometry and superluminescent diode light to acquire simultaneous high-resolution cross-sectional OCT and confocal images of ocular structures. The system includes an optical assembly, light source, power supply, and computer for data analysis and image processing. It is used by clinicians to visualize and measure retinal, macular, and optic disc structures to assist in diagnosing and managing posterior segment ocular diseases. By adjusting focal position, it also images the cornea, sclera, and conjunctiva. Output is displayed to the clinician for diagnostic assessment, aiding in clinical decision-making regarding ocular pathology. ## Clinical Evidence Prospective comparative study of 36 subjects, including normal individuals and patients with retinal or glaucoma pathologies. Evaluated precision and agreement of retinal, RNFL thickness, and optic nerve disc ratio measurements between Spectral OCT/SLO and Stratus OCT. Results showed the device is equivalent or better in precision tests, with regression analysis confirming substantial equivalence to the predicate. ## Technological Characteristics Non-contact tomographic and confocal imaging system. Utilizes low-coherence interferometry with superluminescent diode light source. Hardware includes optical system, power supply, and computer for image processing. Key difference from predicate: uses spectrometer with optical grating and linear CCD camera for signal detection. Software performs data analysis and image processing. ## Regulatory Identification An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye. ## Special Controls *Classification.* Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9. ## Predicate Devices - OCT Ophthalmoscope, Ophthalmic Technologies, Inc ([K042885](/device/K042885.md)) - Stratus OCT, Carl Zeiss Meditec System ([K033123](/device/K033123.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ K080460 Image /page/0/Picture/1 description: The image shows the logo for OPKO Instrumentation/OTI, which is a division of OPKO Health, Inc. The logo is black and white and features the text "OPKO" in bold letters, followed by a slash and "OTI" in a different font. Above the text is the number 14. 510(k) Summary October 1, 2008 NOV 1 4 2008 1. Submitter Information Name: OPKO Instrumentation/OTI 4400 Biscayne Boulevard Miami, FL 33137 | Telephone Number: | 305-575-6004 | |-------------------|--------------| | Fax Number: | 305-575-6016 | Contact Person: Jane Hsiao e-mail: jhsiao@opko.com Date Submitted: October 1, 2008 - 2. Name of Device Trade Name: Spectral OCT/SLO Common Name: Ophthalmoscope using optical coherence tomography Classification Name: Ophthalmoscope, a-c powered, 800HE - 3. Equivalent legally marketed devices. K042885 OCT Ophthalmoscope, Ophthalmic Technologies, Inc K033123 Stratus OCT, Carl Zeiss Meditec System - 4. Description The OPKO/OTI Spectral OCT/SLO is a computerized instrument that employs non-invasive, low-coherence interferometry to acquire simultaneous highresolution cross-sectional OCT (Optical Coherence Tomography) and confocal images of ocular structure, including retina, retinal nerve fiber layer, macula and optic disc of the eye. {1}------------------------------------------------ - 5. Indication for Use: The Spectral OCT/SLO is a non-contact, high-resolution non-invasive tomographic and confocal imaging device. It is indicated for in vivo viewing. axial cross-sectional, and three-dimensional imaging and measurement of posterior ocular structures including: retina, macula, retina nerve fibre lancer and optic disk. It is used as a diagnostic device to aid in the detection and management of ocular diseases affecting the posterior segment of the eye. In addition, cornea, sclera and conjunctiva can be imaged with the system by changing the focal position. - 6. Technological Characteristics: The OPKO/OTI Spectral OCT/SLO and the predicate device, Zeiss Stratus OCT both utilize Optical Coherence Tomography, which relies upon interferometty of superluminescent diode light, reflected from the fundus of the eye, to produce cross-sectional image of the retina. Both systems have similar hardware system consist of an optical system, the light source, a power supply and a computer with software for data analysis and image processing. The two systems differ in the that OPKO/OTI Spectral OCT/SLO uses spectrometer with optical grading and Iinear CCD camera while Stratus OCT uses photo-detector to detect the regurn OCT light signal from the eve. - 7. Performance Data - a. Non-clinical tests The Spectral OCT/SLO has had accuracy test, optical emissions analyses, image comparison, electrical safety test, electromagnetic compatibility test and software validation tests. - b. Clinical tests: Thirty six subjects, including normal and patients with retinal or glaucoma pathologies, participated in a controlled prospective comparative study to evaluate the performance (precision and agreement) of Spectral OCT/SLO and the predicate device Stratus OCT in the measurement of retinal, RNFL thickness and optical nerve disc ratio. - c. Conclusions The Spectral OCT/SLO is equivalent or better in the precision tests when compares to the predicate device. The regression analysis between the measurements are substantially equivalent between the test and the legally marketed predicate devices. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three wavy lines representing its body and wings. The eagle faces left. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" is arranged in a circular fashion around the eagle. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 OPKO Health, Inc. c/o Jane Hsiao, Ph.D. OPKO Health, Inc. 4400 Biscayne Blvd. Miami, Florida 33137 NOV 1 4 2008 Re: K080460 Trade/Device Name: Spectral OCT/SLO Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: II Product Code: OBO Dated: November 11, 2008 Received: November 12, 2008 Dear Dr. Hsiao: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-frec number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Maling B. Egeratas, und Malvina B. Eydelman, M.L Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number: K080460 Device Name: Spectral OCT/SLO Indications For Use: The Spectral OCT/SLO is a non-contact, high-resolution non-invasive tomographic and confocal imaging device. It is indicated for in vivo viewing, axial cross-sectional, and three-dimensional imaging and measurcment of posterior ocular structures including: retina, macula, retinanserve fibre layer and optic disk. It is used as a diagnostic device to aid in the detection and management of ocular diseases affecting the posterior segment of the eye. In addition, corners and conjunctiva can be imaged with the system by changing the focal position. Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR Over-The-Counter Use (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) umtte (Division Sign-Off) Division of Ophthalmic and Ear. Nose and Throat Devices 510(k) Number --- **Source:** [https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K080460](https://fda.innolitics.com/submissions/OP/subpart-b%E2%80%94diagnostic-devices/OBO/K080460) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com